Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Boeree

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
The Journal of Antimicrobial Chemotherapy|October 26, 2019
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patientsCharles M Mtabho, Hadija H Semvua, Jossy van den Boogaard, et al.
Acta Tropica|December 12, 2022
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approachAnna-Maria Mekota, Stephen H Gillespie, Michael Hoelscher, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
The European Respiratory Journal|November 9, 2016
Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the uglyRichard van Altena, Onno W Akkerman, Jan-Willem C Alffenaar, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patientsNorbert Heinrich, Rodney Dawson, Jeannine du Bois, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosisRalf Stemkens, Veronique de Jager, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatmentSven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Frontiers in Immunology|October 17, 2018
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment EfficacyMohamed I M Ahmed, Nyanda E Ntinginya, Gibson Kibiki, et al.
American Journal of Respiratory and Critical Care Medicine|August 18, 2015
A Step toward an Optimized Rifampin Dose CompletedMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|October 26, 2019
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patientsCharles M Mtabho, Hadija H Semvua, Jossy van den Boogaard, et al.
Acta Tropica|December 12, 2022
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approachAnna-Maria Mekota, Stephen H Gillespie, Michael Hoelscher, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
The European Respiratory Journal|November 9, 2016
Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the uglyRichard van Altena, Onno W Akkerman, Jan-Willem C Alffenaar, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patientsNorbert Heinrich, Rodney Dawson, Jeannine du Bois, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosisRalf Stemkens, Veronique de Jager, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatmentSven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Frontiers in Immunology|October 17, 2018
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment EfficacyMohamed I M Ahmed, Nyanda E Ntinginya, Gibson Kibiki, et al.
American Journal of Respiratory and Critical Care Medicine|August 18, 2015
A Step toward an Optimized Rifampin Dose CompletedMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Pageof 13